MediSynergics

MediSynergics is a private U.S. early-stage biotech focused on discovering novel small-molecule therapies for human disease. The company has described work across infectious disease, central nervous system disorders, pain, and cancer, and was founded by former Pfizer scientists Dennis Godek and Harry Howard. Publicly available information indicates it operates from the UConn Technology Incubation Program in Farmington, Connecticut and has conducted internal medicinal chemistry and compound synthesis. Its disclosed pipeline appears to remain preclinical, including an antiparasitic program and an oncology program, with additional historical emphasis on ketamine-derivative pain therapeutics.